Patients can use the tracker to stay up-to-date on GLP-1 availability by drug, dose and location, share their own experience with a shortage or finding supply in their area, and submit shortage reports to the Food and Drug Administration, according to Ro
Dear Editor, The global prevalence of type 2 diabetes and obesity, affecting over 507 million 1 and 890 million 2 individuals, respectively, underscores the urgent need for more effective treatments
Others are technically long-term but come with monitoring requirements, side effects, stopping rules or limits on how much weight patients could expect to lose
More than half of all US adults are eligible for semaglutide therapy
They are super popular for a reason: they work really well, said Dr Christopher Weber, an internist in Milwaukee who only sees patients struggling with obesity
Is the Peptide Calculator free?+ Yes entirely free, no signup, no paywall, no account required